



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Bifikafusp alfa

Cat. No.:	HY-P99479
CAS No.:	1957239-90-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2). Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity [1].								
In Vivo	<p>Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; Female NMRI nude mice with MiaPaca-A2 xenografts) has antitumor activity against established pancreatic cancer^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Female NMRI nude mice with MiaPaca-A2 xenografts^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1.43 and 4.29 MIU/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; daily; for 10 days</td> </tr> <tr> <td>Result:</td> <td>Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.</td> </tr> </table>	Animal Model:	Female NMRI nude mice with MiaPaca-A2 xenografts ^[1]	Dosage:	1.43 and 4.29 MIU/kg	Administration:	Intraperitoneal injection; daily; for 10 days	Result:	Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.
Animal Model:	Female NMRI nude mice with MiaPaca-A2 xenografts ^[1]								
Dosage:	1.43 and 4.29 MIU/kg								
Administration:	Intraperitoneal injection; daily; for 10 days								
Result:	Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.								

REFERENCES

[1]. Wagner K, et, al. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008 Aug 1;14(15):4951-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA